annex 1. - uiccforms.uicc.org/templates/uicc/pdf/cervical/annexes08.pdf · annex 1. example of...
TRANSCRIPT
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G1
ANNEx 1. EXAMPLE OF COUNTRY WORK ON CERVICAL CANCER BY MEMBERS
AustraliaCancer Council G2
BangladeshBangladesh Cancer Society G4
NigeriaCLASP Institute for Women’s Health - UCL G6
United States of AmericaOncology Nursing Society G8
European Union
UruguayProcedimientos del Programa de Prevención del Cáncer de Cuello Uterino de Uruguay G10
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G2
AustraliaCancer Council
Best practice in cervical cancer immunisation
Report of a roundtable discussion about the impactof the human papillomavirus vaccine in Australia
Discussion and recommendations March 2008
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G3
Executive summary
On 18 April 2007, The Cancer Council Australia convened a national roundtable discussion on human papillomavirus (HPV) immunisation and its impact on the National Cervical Screening Program. The aim was to bring leaders in immunisation and screening together to share their expertise, examine the latest evidence and develop recommendations for policy makers. The Australian Government (Commonwealth Department of Health and Ageing) co-sponsored the event.
The roundtable was convened in response to the emergence of a vaccine that prevents two strains of HPV that cause approximately 70% of cervical cancer. While HPV vaccination has the potential to significantly reduce the impact of cervical cancer, its introduction in Australia must be managed in a way that ensures Australia’s successful cervical cancer screening program continues to protect women who, for reasons documented in this report, would not benefit from the vaccine.
The event gathered together the nation’s leaders in cervical cancer policy and implementation, with the key objectives to: identify what information is currently available for health professionals and the community about the HPV vaccine; lead discussion around the impact of HPV vaccination on the National Cervical Screening Program; and generate outcomes and recommendations that can help inform policy and practice.
A key component of the roundtable was a workshop facilitated by Professor Terry Nolan, Head of School, School of Population Health, University of Melbourne, which identified: potential barriers to the successful rollout of the HPV vaccination program; potential barriers to ensuring the National Cervical Screening Program delivers optimal results following the introduction of HPV immunisation; and research questions that need to be addressed in the short and long term. The workshop rated the significance of key interventions under each of these headings, as documented in this report.
The roundtable also featured formal presentations from experts in a range of fields related to cervical cancer control, which are summarised in Attachment 1.
Following lengthy discussion, roundtable participants agreed on five principles around which a set of more detailed recommendations, and agencies with remit to explore them, are documented:
1. Review the National Cervical Screening Program;
2. ‘Central’ overseeing to monitor the HPV vaccine’s impact on the National Cervical Screening Program;
3. Develop an Indigenous ‘package’ for screening and vaccination;
4. Undertake post-implementation evaluation of the National HPV Vaccination Program; and
5. Address information systems issues.
This report lists these recommendations and summarises the discussion and presentations from the roundtable. Publication was deferred to enable additional expert input and to coincide with the subsequent development of the HPV immunisation chapter of The Cancer Council Australia’s National Cancer Prevention Policy.
Full document:Full document: http://www.cancer.org.au//File/PolicyPublications/NCPP/NCPP07-09cervicalca.pdf http://www.cancer.org.au//File/PolicyPublications/NCPP/NCPP07-09cervicalca.pdf
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G4
BangladeshBangladesh Cancer Society
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G5
F o r m o r e i n f o r m a t i o n :F o r m o r e i n f o r m a t i o n :
Prof.Latifa Shamsuddin - [email protected] Shamsuddin - [email protected]
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G6
NigeriaCLASP Institute for Women’s Health - UCL
The First International Open Day to Raise Awareness of Screening for the Prevention
of Cervical Cancer
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G7
BACKGROUND
How the Free Cervical Screening Project Began The idea of setting up a project for cervical screening in Nigeria began when the newly formed Institute for Women’s Health, under the directorship of Prof. Ian Jacobs, received a donation of £500,000, which was to be spent on new projects in developing countries. Adeola Olaitan, Consultant Gynaecologist at University College London Hospital (UCLH) saw an opportunity to use her skills and those of her colleagues to help prevent cervical cancer in Lagos and in November 2005 the project was allocated £50,000. A successful collaboration with Dr Rose Anorlu, Consultant Gynaecologist at the Lagos University Teaching Hospital (LUTH) and Dr Chiara Mezzalira, Medical Director of St Kizito’s Primary Health Care Project saw the launch of a screening program for the prevention of cervical cancer.
Cervical cancer is the second commonest cancer in women world wide, second only to breast. It accounts for half a million cases a year and approximately 80% of these occur in the developing world. 300,000 women die of cervical cancer per annum, more than those who die of complications of childbirth.
There are multiple reasons why cervical cancer is common in Nigeria. There is no effective screening program and awareness of cervical cancer, even among healthcare workers, is low. In addition, HIV infection increases susceptibility to the disease. The majority of women present late and as there is little opportunity for curative treatment and no access to palliative care, most women die a miserable death.
Thus a small, inexpensive intervention such as cervical screening could potentially save numerous lives. It is estimated that screening in the United Kingdom saves 5000 lives per year.
F o r m o r e i n f o r m a t i o n o n C L A S P :F o r m o r e i n f o r m a t i o n o n C L A S P :
Dr Christine EkechiDr Christine [email protected]@doctors.org.uk
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G8
ONCOLOGY NURSING SOCIETY POSITION
It Is the Position of ONS That
The Human Papillomavirus Vaccine and Prevention of Cervical Cancer
®
References
Perspectives on Sexual and Reproduc-tive Health, 36
Vaccine, 23
CA: A Cancer Journal for Clinicians, 57
United States cancer statistics: 2003 incidence and mortality.
Approved by the ONS Board of Directors, 10/07.
United States of AmericaOncology Nursing Society
June 24, 2008
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G9
European Union
To obtain a ful l copy please contact the press off ice: To obtain a ful l copy please contact the press off ice:
press.o�[email protected] http://www.consilium.europa.eu/Newsroompress.o�[email protected] http://www.consilium.europa.eu/Newsroom
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G10
UruguayProcedimientos del Programa de Prevención del Cáncer de Cuello Uterino de Uruguay
Comisión Honoraria de Lucha Contra el Cáncer
Programa Nacional de Control de Cáncer
Ministerio de Salud Pública
Montevideo, 2008
ESTRATEGIAY
MANUAL DE PROCEDIMIENTOS
Programa de Prevenciónde Cáncer de Cuello Uterino
en el Uruguay ”Dr. Enrique Pouey”
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G11
F o r m o r e i n f o r m a t i o n :F o r m o r e i n f o r m a t i o n :
Dr. Guillermo Rodríguez www.urucan.org.uyDr. Guillermo Rodríguez www.urucan.org.uy
El Programa de Prevención del Cáncer de Cuello Uterino (PPCCU) surge en el Uruguay enel año 1994 por iniciativa de la Comisión Honoraria de Lucha contra el Cáncer (CHLCC)como una experiencia piloto en el área de influencia del Hospital Saint Bois en Montevideo,la capital de Uruguay. Esta experiencia se extiende progresivamente a otros departamen-tos del interior del país, con complementación de recursos de los Hospitales del Ministeriode Salud Pública (MSP). Posteriormente se coordinan actividades con algunas Intenden-cias Municipales adquiriendo la forma de una compleja organización con personas quedependen de diversas instituciones, que componen áreas técnicas y administrativas condiferentes niveles de acción.A nivel de la CHLCC se plantea la extensión del PPCCU a todo el Uruguay, en coordinacióncon el Programa Nacional de Control de Cáncer (PRONACCAN). Por este motivo se soli-cita el asesoramiento de la Unión Internacional contra el Cáncer (UICC), realizándose lassiguientes actividades:
• Seminario en Paysandú, Uruguay, sobre Organización, Control de Calidad y Evalua-ción de un programa de prevención del cáncer de cuello de útero, con la participa-ción de las Dras. Hélène Sancho Garnier (Francia), Leticia Fernández Garrote (Cuba)y Lisseth Ruiz de Campos (El Salvador), como profesoras y Maria Stella de Sabata,jefa de Prevención y Detección Temprana de Cáncer, UICC (Unión InternacionalContra el Cáncer) Noviembre, 2005.
• Primera Asesoría local de UICC en Mayo de 2006 con trabajo práctico y analíticosobre la organización del Programa, el sistema de información, visitas a laboratoriosde citología, Unidades de toma de muestra de PAP y Unidades de colposcopía. Dras.Leticia Fernández Garrote (Cuba) y Lisseth Ruiz de Campos (El Salvador).
• Segunda Asesoría local de UICC en Diciembre de 2006 para el desarrollo del siste-ma de información, control de calidad de los laboratorios y elaboración del Manualdel Programa. Visitas a Centros Asistenciales de segundo y tercer nivel. Dras. LeticiaFernández Garrote (Cuba) y Lisseth Ruiz de Campos (El Salvador).
• Tercera Asesoría local de UICC 1º a 15 de Junio de 2007 «Aprobación de la primeraversión del manual del Programa, desarrollo del sistema de información y sistemainformático nacional, implementación de un plan de reclutamiento de la poblaciónobjetivo, instrumentación del sistema de control de calidad de la citología y de cursosde formación de citotécnicos para el PPCCU.» Prof. Hélène Sancho Garnier (Fran-cia), Dra. Leticia Fernández (Cuba) y Dra. Lisseth Ruiz De Campos (El Salvador).
Este documento pretende ubicar al actor, participante activo del Programa dentro del es-quema organizativo, así como conocer todos los módulos que lo componen con la informa-ción mínima indispensable de cada uno de ellos.Para su escritura se utilizó la información epidemiológica internacional y de Uruguay publi-cada por International Agency for Research on Cancer (IARC), y del Registro Nacional deCáncer de Uruguay. Se tomó en cuenta la información obtenida por el PPCCU que desdehace trece años ha implementado la CHLCC en Montevideo y varias localidades del interiordel país.Se realizaron reuniones con amplia participación de técnicos locales.
Prefacio
Se elaboró un documento preliminar, que fue aprobado en su primera versión, luego continuó perfec-cionándose hasta llegar a la versión actual, que contó con la contribución inestimable de un grupo deexpertos locales en las diferentes áreas temáticas del Programa (cuya lista se adjunta a continuación)y la revisión exhaustiva de las consultoras internacionales.Creemos que es importante destacar que la tarea de cada uno es indispensable y que la suma de lasacciones de todos en el fiel cumplimiento de los objetivos específicos planteados, determina el éxitode esta tarea.
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G12
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G13
ANNEX 2. EVIDENCE OFCOUNTRY SUPPORT FOR IMPROVEDCERVICAL CANCER PREVENTION
About the dossier
This dossier was compiled by Cervical Cancer Action and PATH. It may be freely shared for educational and non-commercial purposes.
Cervical Cancer Action is an advocacy coalition with the goal of expediting global availability, affordability and accessibility of new cervical cancer prevention tools; strategic advocacy for expanded political will and financial commitment and civil society mobilization and support. Sign the Global Call to Stop Cervical Cancer at www.CervicalCancerAction.org.
PATH, a founding member of Cervical Cancer Action, is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. For more information, please visit www.path.org.
For more information about cervical cancer, please visit RHO Cervical Cancer at www.rho.org.
The dossier will be available at www.rho.org/CCAdossier The dossier will be available at www.rho.org/CCAdossier
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G14
ANNEX 3. ECCAEUROPEAN CERVICAL CANCER ASSOCIATION.
STOP Cervical Cancer in Europe
Every year in Europe, 50,000 women develop and 25,000 women die from cervical cancer. Effective, organised cervical cancer screening can prevent up to 80% of cervical cancers. New technologies, if properly implemented within organised programmes, have the potential to reduce cervical cancer rates even further and prevent almost every case of this disease in Europe.
We, the undersigned, call upon the European Parliament, the European Commission and all national governments of Europe to:
Work together to implement effective cervical cancer prevention programmes in compliance with the recommendations of the Council of the European Union and the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Support the establishment of public health education programmes to ensure that all women are aware of the importance of cervical cancer prevention and take full advantage of the services that are available to them.
Facilitate the exchange of best practice between the countries of Europe so that all can benefit from the world-class expertise that exists within Europe.
Support independent research to establish the most appropriate means to implement new screening methods and vaccination against the Human Papillomavirus (HPV) to ensure the greatest reductions in cervical cancer across Europe.
Recognise and support the essential role played by charities, non-governmental organisations, patient support groups and volunteers in the ongoing reduction of cervical cancer in Europe.
1.
2.
3.
4.
5.
F o r m o r e i n f o r m a t i o n : F o r m o r e i n f o r m a t i o n :
http://www.ecca.info/webECCA/en/http://www.ecca.info/webECCA/en/
http://www.cervicalcancerpetition.eu/http://www.cervicalcancerpetition.eu/
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G15
What is cervical cancer?
Cervical cancer develops in the cervix, the part of the
uterus that opens into the vagina. It occurs when cells
of the cervix become abnormal and start to grow in an
uncontrolled fashion.
It takes many years for abnormal cells in the early stages to
progress to cervical cancer. Fortunately, these stages are
easy to treat. However, they show no obvious signs and
can only be found by screening.
Why get screened?
Cervical screening is designed to find abnormal cervical
cells in the early stages when they can be removed so
they do not develop into cervical cancer. Once cancer has
developed, treatment becomes much more difficult and less
successful.
Who should be screened?
All women from 25 to 65 years of age should be screened.
Women who are 25 to 49 years of age should be screened
once every 3 years, while those from 50 to 64 years of age
should be screened every 5 years.
You can stop screening at the age 65 if you have been
regularly screened since you were 50 and have not had any
recent abnormal results.
What do you need to do?
If you are registered with a GP, you should receive a letter
when it is time for you to have your cervical smear.
If it has been more than five years since your last smear,
contact your GP to make sure that you are registered. You
will then need to make an appointment; this should be at the
middle of your menstrual cycle, about 2 weeks after the end
of your last period.
When you call to book, they will tell you what you need to do
to prepare. In general, you should avoid using any treatments
inside your vagina for 2 days before your appointment and
avoid having sex the night before.
How does screening work?
Cervical screening is done using the cervical
smear test which is taken at your GP
practice or family planning clinic. This is a
simple procedure that only takes about
ten minutes and involves little more
than a vaginal examination. During the
examination, a sample of cells will be
taken from your cervix using a small
spatula or brush.
Cervical cancer is caused by certain types of HPV. There
are more than 100 types of HPV and about 15 of these
can cause cervical cancer.
Most adults will have had a HPV infection at some time
in their lives, but it usually disappears on its own without
any problem. If the HPV does not disappear, it can
increase the risk of cervical cancer developing.
Vaccination is now available to protect women against
the 2 most common types of HPV, types 16 & 18, which
cause about 2/3rds of all cervical cancers and many
abnormal Pap tests. The current vaccines will be most
effective if given before you have had HPV 16 or 18, and
they will not effectively protect against all HPV types.
Therefore, even if you have been vaccinated, you should
still be screened. Together, screening and vaccination
will offer the most effective protection against cervical
cancer.Human Papilloma Virus (HPV) and Cervical Cancer
cervical smear result?
Most women will have a normal result.
In this case, your risk for cervical cancer is low and you
should continue your regular screening.
Is screening reliable?
No screening test is perfect and the cervical smear test may
miss some cases of disease. This is why you need to be
screened regularly, so that anything that has been missed
on one screen may be picked-up at the next, before it has
time to progress.
High-quality, organised screening programs are very
effective, but will not prevent all cervical cancers.
Normal
cervical smear result?
Some women will have an abnormal result. This simply
means that some abnormal cervical cells have been found
on the cervical smear test; it is very rare for cancer to be
detected.
Depending on the result, you will be advised to have one
of the following:
• another cervical smear in three to six months
• a colposcopy, which is a procedure that allows the doctor
to examine your cervix more closely.
Certain abnormalities should be removed so that they will
not develop into cancer. This usually requires only a simple
procedure that can be done in the hospital gynaecology
outpatient clinic. Treatment rarely affects your sex life or
ability to have children.
Abnormal
Uterus
Cervix
Vagina
These cells will be sent to the laboratory, where they will be
examined under a microscope to search for any abnormal
cervical cells.
Why get vaccinated?
Vaccination has been shown to effectively prevent:
• infection with HPV types 16 and 18, the two most
common cancer-causing types of HPV,
• the development of abnormal cervical cells caused by
these types.
Because of this, vaccination will reduce the risk of needing
treatment for abnormal cervical cells and it should reduce
the risk of cervical cancer.
One vaccine also protects against HPV 6 and 11 that cause
most cases of genital warts.
Vaccination prevents HPV infection occurring in the first
place. However, HPV is very common and many women
are infected soon after the start of sexual activities.
Because of this, vaccination will provide the best protection
if given before the start of sexual activities, and may be less
effective in sexually active teens or women.
How long does vaccination protect?
Should boys or men be vaccinated?
Although men cannot get cervical cancer, they can pass-
on HPV to their partner.
However, vaccination is not recommended for males in
the UK as we do not yet know if it will effectively prevent
HPV infection in males. This is now being studied and the
vaccines may be recommended for use in boys and men
in the future.
Is vaccination safe?
Vaccination appears to be safe. The clinical trials show only
minor reactions typical of any vaccination (swelling, itching,
redness at the injection site and less frequently fever, nausea,
and dizziness).
HPV vaccination is not recommended for pregnant women.
Does vaccination provide complete
protection against cervical cancer?What is cervical cancer?
Cervical cancer develops in the cervix, the part of the
uterus that opens into the vagina. It occurs when cells of
the cervix are infected with HPV, become abnormal and
start to grow in an uncontrolled fashion.
Vaccination effectively prevents the development of
abnormal cervical cells due to the HPV types in the vaccine.
However, it has not been shown to protect women who
have HPV 16 or 18 at the time they are vaccinated. Also,
vaccination does not protect against all of the other HPV
types that can cause cervical cancer.
For these reasons, vaccination does not provide
complete protection against cervical cancer. Even
if you have been vaccinated, it is
important to continue with regular
cervical screening so that any
abnormal cervical cells can be found
at an early stage when they can be
easily removed to prevent a cancer
developing.
There are about forty different types of Human Papilloma
Virus (HPV) that can infect the genital tract. Some of these
may cause abnormal cervical cells that can progress to
cervical cancer. HPV types 16 & 18 are among the most
common types associated with cervical cancer, causing
about 2/3 of cases and many abnormal Pap smears.
Other types of HPV can cause genital warts. HPV types
6 and 11 cause the majority of cases of genital warts but
are not associated with cervical cancer.
Genital HPV can be spread by any form of sexual
contact. It is very common and can occur at any time, but
most people will get HPV soon after the start of sexual
activities. Fortunately, most of them will fight-off their
HPV and it will clear within 24 months without causing
any problems. While a woman has HPV, it can produce
the abnormal cells found on her cervical smear, but these
also usually disappear once the virus has gone.
The problem occurs when some women do not clear their
HPV. In these cases, the abnormal cervical cells may, over
time, develop into cervical cancer if they are not detected
through screening and removed. Currently, there is no way
to tell who will clear their virus and who will not.Human Papilloma Virus & Cervical Cancer
Vagina
Uterus
Cervix
Who should be vaccinated?
In the UK, one HPV vaccine has been licensed for use
in children and adolescents aged 9 to 15 years, and in
adult females aged 16 to 26 years. In addition, the Joint
Committee on Vaccination and Immunisation (a committee
of the Department of Health) has advised that girls aged 12
to 13 should be vaccinated on the NHS. However, official
recommendations are not expected until later in 2007.
The current vaccine is given as three injections over six
months. At present, we know that vaccination offers good
protection against the HPV types in the vaccine and disease
caused by these types for at least 5 years, which is the
length of time women have been followed up in the clinical
trials so far. Studies are underway to see how much longer
the protection will last.
Human Papilloma Virus (HPV):
the cause of cervical cancer
Does vaccination provide complete
protection against cervical cancer?What is cervical cancer?
Cervical cancer develops in the cervix, the part of the
uterus that opens into the vagina. It occurs when cells of
the cervix are infected with HPV, become abnormal and
start to grow in an uncontrolled fashion.
Vagina
Uterus
Cervix
In the UK, one HPV vaccine has been licensed f
in children and adolescents aged 9 to 15 y
adult females aged 16 to 26 years. In addition, th
Committee on Vaccination and Immunisation (a c
of the Department of Health) has advised that girls ag
to 13 should be vaccinated on the NHS. However, o
• What is cervical cancer?
• Why get vaccinated?
• Who should be vaccinated?
• Does vaccination provide complete protection against cervical cancer?
• How long does vaccination protect?
• Should boys or men be vaccinated?
• Is vaccination safe?
VACCINATION AGAINSTHPV AND CERVICAL CANCER
• Vaccination provides very effective protection against the 2 most common types of HPV, HPV 16 & 18, that are responsible for about 2/3 of cervical cancers and many abnormal Pap smears, but does not protect against all the HPV types associated with the development of cervical cancer.
• Vaccination prevents HPV infection occurring in the first place. Therefore it provides the greatest protection if given before the start of sexual activities.
• Vaccination has not been shown to offer protection against disease if you have HPV 16 or 18 when you are vaccinated. Therefore, the benefits of vaccination may be less in women who are already sexually active as some will be infected with one or both of these types.
• The current vaccine appears to be safe with the clinical trials showing only minor reactions typical of any vaccination.
• Vaccination against HPV reduces the risk of cervical cancer but does not eliminate it. Even if you have been vaccinated, it is important to continue with regular cervical screening.
VACCINATION AGAINST HPV AND CERVICAL CANCER
The ECCA supports the reduction of cervical cancer in Europe by promoting awareness of cervical cancer and the means by which it can be prevented. Drawing upon the expertise of researchers, clinicians and public health organisations from across Europe, the ECCA has prepared:
The leaflets • Cervical cancer screening• Human Papilloma Virus (HPV) and cervical cancer• Follow-up and treatment of an abnormal cervical smear• Vaccination against HPV and cervical cancer
The booklets • Everything you need to know to help you avoid cervical
cancer• Everything you need to know if you have an abnormal
cervical smear
For additional information Visit our website: www.ecca.info Send your questions to: [email protected]
ECCA
Pho
tos
: Get
ty Im
age
/ S
tock
byt
e
© ECCA 2007
L4_E
N_U
K_A
What is cervical cancer?
Cervical cancer develops in the cervix, the part of the
uterus that opens into the vagina. It occurs when cells
of the cervix become abnormal and start to grow in an
It takes many years for abnormal cells in the early stages to
progress to cervical cancer. Fortunately, these stages are
Who should be screened?
All women from 25 to 65 years of age should be screened.
Women who are 25 to 49 years of age sho
once every 3 years, while those from 50 to 64
should be screened every 5 years.
You can stop screening at the age 65 if
regularly screened since you were 50 and have
recent abnormal results.
• What is cervical cancer?
• Why get screened?
• Who should be screened?
• What do you need to do?
• How does screening work?
• Normal cervical smear result?
• Abnormal cervical smear result?
• Is screening reliable?
CERVICAL CANCERSCREENING
• Cervical cancer develops in the cervix, the part of the uterus that opens into the vagina. It occurs when cells of the cervix become abnormal and start to grow in an uncontrolled fashion.
• Cervical screening is designed to find abnormal cervical cells in the early stages when they can be easily removed so they do not develop into cervical cancer. Cervical screening is currently done using the cervical smear test.
• All women from 25 to 65 years of age should be screened. Women who are 25 to 49 years of age should be screened once every 3 years, while those from 50 to 64 years of age should be screened every 5 years.
• Vaccination is now available to reduce the risk of cervical cancer, but it will not eliminate need for screening. Together, screening and vaccination will offer the most effective protection against cervical cancer.
CERVICAL CANCER SCREENINGECCA
Pho
tos
: Get
ty Im
age
/ S
tock
byt
e
© ECCA 2006
L1_E
N_U
K_C
BRITISH SOCIETY FOR COLPOSCOPY AND CERVICAL PATHOLOGY
British Association for Sexual Health & HIV
The ECCA supports the reduction of cervical cancer in Europe by promoting awareness of cervical cancer and the means by which it can be prevented. Drawing upon the expertise of researchers, clinicians and public health organisations from across Europe, the ECCA has prepared:
The leaflets • Cervical cancer screening• Human Papilloma Virus (HPV) and cervical cancer• Follow-up and treatment of an abnormal cervical smear• Vaccination against HPV and cervical cancer
The booklets • Everything you need to know to help you avoid cervical
cancer• Everything you need to know if you have an abnormal
cervical smear
For additional information Visit our website: www.ecca.info Send your questions to: [email protected]
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G16
ANNEx 4. USEFUL LINKS
Alliance for Cervical Cancer Prevention
American Cancer Society: AIDS-related cancers
American Cancer Society: guideline for detection
American Cancer Society: HPV vaccine recommendations
Centres for Disease Control and Prevention, USA
Cervical Cancer Action
ECCA
European Commission
Genital HPV infection
HPV Vaccine: Q&A for the public
Human papilloma viruses and cancer
International Agency for Research on Cancer
JHPIEGO
Pan-American Health Organization
PATH
RHO Cervical Cancer
What is the HPV virus?
World Health Organizationhttp://www.who.int/hpvcentre/en/
International Agency for Research on Cancer (IARC)http://screening.iarc.fr/digitallearningserie.php
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G17
AFRICABurundiDr Rosa Paula [email protected]
Ethiopiawww.mathycancersoc.org
NigerDr Hadiza Nathalie [email protected]
Nigeriahttp://www.copebc.com/www.socron.net/socron/ (Society of oncology and cancer research of Nigeria)
Tunisiawww.atcc.org.tn
UgandaDr Gertrude [email protected]
AUSTRALASIA/ASIAAustraliaCancer councilhttp://www.cancer.org.au/Home.htmQueenslandwww.qldcancer.com.auSouth Australia www.cancersa.org.au Victoriawww.cancervic.org.au
BangladeshProf.Latifa Shamsuddin [email protected]
IndiaWIA Dr Rajkumar [email protected] Gujaratwww.cancerindia.orgTATAhttp://tmc.gov.in/
Indonesiawww.kankerindo.org
Malaysiawww.radiologymalaysia.org/breasthealth/bcwaindex.htm
Pakistanhttp://www.shaukatkhanum.org.pk/
Taiwanhttp://ecancer.org.tw
Viet [email protected]
EuropE
Belgiumhttp://www.cancer.be/index.cfm?fuseaction=home&Lang=NL
Denmarkhttp://www.cancer.dk/Cancer/forside+cancerdk.htm
Estoniahttp://www.cancer.ee/?op=&id=&cid=
Francehttp://www.ligue-cancer.net/http://www.cjp.fr/
Germanyhttp://www.dkfz.de/index.html
ItalyAIOMhttp://www.aiom.it/AIMaChttp://www.aimac.it/
Nothern Irelandhttp://www.ulstercancer.org/
Norwayhttp://www.kreftforeningen.no/
Portugalhttp://www.ligacontracancro.pt/
SlovakiaDr Eva [email protected]
SpainAEEC .http://www.todocancer.org/FECEChttp://www.fecec.org/contents/home.phpICOhttp://www.iconcologia.net/
Switzerlandhttp://www.swisscancer.ch/index.php?id=�14
Turkeywww.turkcancer.org
For more information on the signatories:
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G18
UKCRUKhttp://www.cancerresearchuk.org/CLASPDr Christine [email protected]
LATIN AMERICAArgentinaHenry moorewww.hmoore.com.arSLACOMhttp://www.slacom.org/LALCEChttp://www.lalcec.org.ar/
Dominican [email protected]
Hondurashttp://www.ccancer.hn/
MexicoAMLCChttp://www.amlcc.org/Instituto Nacionalhttp://www.incan.edu.mx/
Uruguayhttp://www.urucan.org.uy/
MIDDLE EASTIsraelhttp://www.cancer.org.il/
Lebanonhttp://www.cancer.org.lb/
North AmEricA
CanadaBCCAhttp://www.bccancer.bc.ca/default.htmNova Scotiahttp://www.cancercare.ns.ca/CHUMhttp://www.chumontreal.qc.ca/Québequehttp://www.fqc.qc.ca/PHA Canadahttp://www.phac-aspc.gc.ca/index-eng.php
USAASCOhttp://www.asco.org/IPOShttp://www.ipos-society.org/about/org/mission.htmONShttp://www.ons.org/
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G19
Dürst, M. et al. Proc. Natl. Acad. Sci. USA, 80: �812-�815, 198�
Boshart, M. et al. EMBO J. �, 1151-1157, 1984
Saslow, D. et al. CA Cancer J. Clin. 57: 7-28, 2007
Cancer Atlas, Am. Cancer Soc. 2006
Pagliusi, S. http://who.int/vaccine_research/diseases/hpv/en/
Clifford, G.M. et al.Br. J. Cancer 89: 101-105, 200�
Ries, L. et al. SEER Cancer Statistics Review 197�-200�, 2006
Daling, J.R. et al. Cancer 101: 270-280, 2004
Schiffman, M et al. J. Natl. Cancer Inst. Monogr. �1: 14-19, 200�
Rubin, M.A. et al. Am. J. Pathol. 159: 1211-1218, 2001
Daling, J.R. et al. Gynecol. Oncol. 84: 26�-270, 2002
Forastiere et al. N. Engl. J. Med. �45: 1890-1900, 2001
Herrero, R. et al. J. Natl. Cancer Inst. 95: 1772-178�, 200�
Kreimer, A.R. et al. Cancer Epidemiol. Biomarers Prev. 14: 467-475, 2005
Geer, C.E. et al. J. Clin Microbiol. ��: 2058-206�, 1995
Munk, C. Et al. Sex. Transm. Dis. 24: 567-572, 1997
Cubilla, A.L. et al. Am. J. Surg. Pathol. 24: 505-512, 2000
Silver, R.D. et al. Otolaryngol. Head Neck Surg. 129: 622-629, 200�
Lele, S.M. et al. Arch. Pathol. Lab. Med. 126: 1184-1188, 2002
International Agency for Research on Cancer (IARC) Handbooks on Cancer Prevention: Cervix cancer Screening. Vol. 10, 2005
Sawaya, G.F. and Washington, A.E. Clin. Obstet. Gynecol. 42: 922-9�8, 1999
Clifford, G.M. et al. Br. J. Cancer 88: 6�-7�, 200�
Castellsague, X. et al. J. Natl. Cancer Inst. 98: �0�-�15, 2006
zur Hausen, H. Infections causing Human Cancer. Wiley-VCH publisher, 2006
Winer, R.L. et al. J. Infect. Dis. 191: 7�1-7�8, 2005
Woodman, C.B. et al. Lancet �57: 18�1-18�6, 2001
Winer, R.L. et al. N. Engl. J. Med. �54:2645-2654, 2006
Pham, T.H. et al. Int. J. Cancer 104: 21�-220, 200�
Cates, W. Jr. Sex. Transm. Dis. 26 (suppl.): 2-7, 1999
Koutsky, L. Am. J. Med. 102: �-8, 1997
Myers, E.R. et al. Am. J. Epidemiol. 151: 1158-1171, 2000
1.
2.
�.
4.
5.
6.
7.
8.
9.
10.
11.
12.
1�.
14.
15.
16.
17.
18.
19.
20.
21.
22.
2�.
24.
25.
26.
27.
28.
29.
�0.
�1.
ANNEx 5. REFERENCES FROM CONCEPT PAPER
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G20
Koutsky, L. et al. N. Engl. J. Med. �47: 1645-1651, 2002
Harper, D.M. et al. Lancet �64: 1757-1765, 2004
Villa, L.L. et al. Lancet Oncol. 6: 271-278, 2005
The Future II Study Group N. Engl. J. Med. �56:1915-27, 2007
US Food and Drug Administration. Product Approval Information-Licensing Action: GARDASIL. http://www.fda.gov/cher/products/hpvmer060806qa.htm
Ho, G.Y. et al. N. Engl. J. Med. ��8: 42�-428, 1998
Ho, G.Y. et al. Cancer Epidemiol. Biomarkers Prev. 1�: 110-116, 2004
Winer, R.L. et al. Am. J. Epidemiol. 157: 218-226, 200�
Peyton, C.L. et al. J. Infect. Dis. 18�: 1554-1564�, 2001
Partridge, J.M. et al. J. Infect. Dis. 196(8):1117-9, 2007
Garland, S.M. et al. N. Engl. J. Med. �56: 1928-4�, 2007
Barnabas, R.V. et al. PLOS Med. �: e1�8, 2006
Sanders, G.D. and Taira, A.V. Emerg. Infect. Dis. 9: �7-48, 200�
Wheeler, C.M. et al. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. J. Infect. Dis. 194: 1291-1299, 2006
Schiffman, M. et al. Lancet �70, 890-907, 2007
Shankar, R et al. Lancet �70(9585):�65-6, 2007
�2.
��.
�4.
�5.
�6.
�7.
�8.
�9.
40.
41.
42.
4�.
44.
45.
46.
47.
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
G21
ANNEx 6 MODEL LETTERS
If you would like to add your voice to the global effort for improved cervical cancer prevention worldwide, please send us a signed letter on your organization’s letterhead by mail, fax or email.
Si vous désirez apporter votre soutien a l’effort mondial pour une prévention organisée contre le cancer du col de l’utérus dans le monde, faites nous parvenir une lettre signée sur papier en-tête par courrier, fax ou e-mail.
Si usted desea apoyar el esfuerzo de movilización de la UICC a favor de una prevención integral del cáncer cervicouterino, envíenos una carta membreteada y firmada por correo, fax o e-mail
Cervical Cancer InitiativeInternational Union Against Cancer UICC62 rte de Frontenex1207 GenevaSwitzerlandFax: +41 (0)22 809 18 10E-mail: [email protected]
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G22
English
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
To the International Union Against Cancer (UICC),
We understand the UICC is gathering evidence for improved cervical cancer prevention. By means of this letter, we would like to show our commitment to the global effort to eliminate cervical cancer worldwide and provide those who need it most with affordable and effective prevention strategies.
Cervical cancer is the second largest cause of death from cancer in women worldwide. For women in developing countries, it is the biggest cancer killer. Virtually all cervical cancer is caused by infection with human papilloma virus (HPV), the most common viral infection of the reproductive tract.
In industrialized countries, expanded screening and treatment have dramatically reduced cervical cancer rates over the last 60 years. But in developing countries, where the vast majority of women never have a pap smear, the incidence and death rates from cervical cancer continues to rise.
Recognizing the potential of the new HPV vaccines to prevent cervical cancer, The World Cancer Declaration calls for HPV vaccination programmes in low and middle-income countries where the burden of cervical cancer is high and calls for specific actions to reduce costs and provide public and professional education, public policy and research.
We recognize that vaccination programmes need to be based on what is affordable, feasible, and culturally acceptable in our country and that vaccination is not a substitute for screening.Cervical cancer is preventable and we are now in an unprecedented position where new technology provides us with the means to make a difference. HPV vaccines given to young girls now can prevent future infections and save numbers of lives for decades to come. Furthermore, improved screening methods could make efficient screening a reality, even in the most remote settings.
We share your commitment to work with governments and other sectors to make cervical cancer prevention work.
Name:Position:Organization:Country:E-mail:
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G24
French
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
À l’attention de l’Union Internationale Contre le Cancer – UICC
Nous soutenons l’effort de mobilisation de l’UICC au niveau mondial et local en faveur d’une prévention organisée contre le cancer du col de l’utérus. Cette lettre témoigne de notre engagement dans l’effort pour éliminer le cancer du col dans le monde et donner accès à des stratégies de prévention efficaces et abordables aux femmes qui en ont le plus besoin.
Le cancer du col est la deuxième cause de mortalité par cancer pour les femmes du monde entier. Pour les femmes des pays en voie de développement, c’est le cancer le plus meurtrier. Pratiquement tous les cas de cancer du col sont dus à une infection par le virus Papilloma humain (HPV), l’infection des organes génitaux la plus fréquente
Dans les pays industrialisés, l’extension des dépistages et les traitements des lésions précancéreuses a contribué à une baisse spectaculaire des taux de cancer du col de l’utérus durant les soixante dernières années. Cela contraste avec la situation des pays en voie de développement qui sont lourdement touchés par 85% des cas de cancer du col et où les taux continuent d’augmenter, alors que la majeure partie des femmes de ces régions ne sont jamais ni dépistées ni traitées.
Après évaluation du potentiel préventif des nouveaux vaccins contre le cancer du col, la Déclaration Mondiale Contre le Cancer réclame des programmes de vaccination contre le HPV pour les pays à faibles et moyens revenus. Elle réclame également des mesures spécifiques pour réduire les coûts, former les professionnels de la santé, et informer la population.
Néanmoins, il est clair que les programmes de vaccination doivent être développés en fonction de ce qui est abordable, réalisable et culturellement acceptable dans chaque pays, de plus, la vaccination ne se substitue pas au dépistage.
Le cancer du col de l’utérus n’est pas une fatalité et les nouvelles technologies fournissent désormais les moyens nécessaires pour modifier le cours de ces cancers. Aujourd’hui, la vaccination des jeunes filles contre le HPV permet d’éviter les conséquences d’infections futures et de sauver bon nombre de vies durant les décennies à venir. De plus, une adaptation des méthodes de dépistage peut faire du dépistage une réalité, même dans les pays les plus défavorisés.
Nous soutenons votre engagement auprès des gouvernements et des autres institutions pour faire de la prévention contre le cancer du col de l’utérus une réalité.
Nom:Titre/position:Organisation:Pays:E-mail:
Su
pp
or
t
ce
rv
ica
l c
an
ce
r
pr
ev
en
tio
n
G26
Spanish
Ce
rv
ic
al
C
an
ce
r
In
it
ia
ti
ve
A la Unión Internacional Contra el Cáncer (UICC),
Apoyamos el esfuerzo de movilización de la UICC a nivel mudial y local a favor de una prevención integral del cáncer cervicouterino. Por medio de esta carta, queremos demostrar nuestro compromiso en el esfuerzo para eliminar a nivel mundial el cáncer cervicouterino y dar acceso a estrategias de prevención accesibles y efectivas a las mujeres que tienen la mayor necesidad.
Para las mujeres en países en desarrollo el cáncer cervicouterino es la primera causa de mortalidad por cáncer en mujeres y la segunda causa a nivel mundial. Prácticamente todos los casos de cáncer cervicouterino se deben al virus de papiloma humano (VPH), la infección viral más común del tracto reproductivo femenino.
En países industrializados, la implementación de la detección temprana, programas de tamizaje y tratamiento ha reducido dramáticamente las tasas de cáncer cervicouterino en los últimos 60 años. Pero en los países en desarrollo, donde la gran mayoría de mujeres nunca se han hecho un control, la incidencia y tasas de mortalidad de cáncer cervicouterino continúan creciendo.
Reconociendo el potencial de las nuevas vacunas contra el VPH para prevenir el cáncer cervicouterino, la Declaración Mundial del Cáncer reclama programas de vacunación de VPH en países de bajos y medianos ingresos, donde la incidencia del cáncer cervicouterino es alta. La Declaración también reclama acciones específicas para reducir los costos de la vacuna y proveer educación pública y profesional, normas públicas e investigación.
Reconocemos que los programas de vacunación necesitan estar basados en lo que es asequible, factible, y culturalmente aceptable en nuestro país y que la vacunación no substituye al tamizaje.
El cáncer cervicouterino es prevenible y estamos ahora en una posición sin precedentes donde las nuevas tecnologías nos proveen con los medios para un cambio significativo. Las vacunas de VPH aplicadas a mujeres jóvenes ahora pueden prevenir infecciones futuras y salvar gran cantidad de vidas por décadas a venir. Más aún, una mejor adaptación de los métodos de tamizaje pueden hacer realidad la detección eficaz, aún en los escenarios más remotos.
Compartimos vuestro compromiso de trabajar con los gobiernos y otros sectores para hacer que la prevención del cáncer cervicouterino sea una realidad.
Nombre:Título/posición:Organización:País:E-mail:
Supporting improved cervical cancer prevention worldwide
D O S S I E R O F S U P P O RTAugust 2008
About UICCFounded in 1933, the International Union Against Cancer (UICC) is the leading international nongovernmental
organization dedicated exclusively to the global control of cancer. Its vision is of a world where cancer is eliminated as a
major life-threatening disease for future generations.
UICC is a non-profit organization. Its objective is to advance scientific and medical knowledge in research, diagnosis,
treatment and prevention of cancer and to promote all other aspects of the campaign against cancer throughout the
world. Members are voluntary cancer leagues and societies, cancer research and treatment centres and, in some countries,
ministries of health.
UICC focuses on cancer prevention and control, tobacco control, knowledge transfer, capacity building, and patient
advocacy and support. It organizes the World Cancer Congress held every two years, and annual symposia, workshops and
training courses with extensive expert networks.
It launched a World Cancer Campaign in 2005 and coordinates World Cancer Day on 4 February each year.
UICC fellowships help train researchers, clinicians, health professionals and cancer workers across the world. Between
them, GLOBALink (the online tobacco control community) and the Global Cancer Control Community service over 7,000
researchers and professionals.
UICC publishes the International Journal of Cancer, books in the TNM and prognostic factors series, a calendar of
international cancer conferences, and technical reports, newsletters and manuals.
UICC is governed by its members through a general assembly, which meets every two years, and an elected board of
directors. With over 300 members in more than 100 countries, UICC is a resource for action and a voice for change.
T H A N K Y O U